Published in Health Risk Factor Week, May 3rd, 2005
Developed by Fujirebio Diagnostics, Inc., (FDI), the Architect CA 125 II assay aids in monitoring patients with ovarian cancer while the Architect CA 15-3 test aids in monitoring stage II and stage III breast cancer. Both tests supply doctors with the critical information they need to determine how patients are responding to treatment.
"Providing laboratories with excellent precision and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Risk Factor Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.